Puma Biotechnology, Inc. (PBYI) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
the bull case· 3
18
disclosed supplier and customer ties in sec filings
sec filingsedgar162
managers reporting a position in thirteen f filings
13fJun 30 '26+7.03%
change in shares held by the ten largest reporting managers
13fJun 30 '26the bear case· 4
5 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized3
of the funds on file reporting a position in pbyi
n-portas of Jun 30 '2610 of 25
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2622
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Puma Biotechnology, Inc. moves with most closely, none share its SEC classification.
Measured against 129 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
PBYI (Puma Biotechnology, Inc.) has 2 disclosed suppliers and 16 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
161 managers report a position worth $314.5M between them, and 22 of them hold 80% of it.
High 9.62 at 3:15 pm ET, low 9.45 at 9:45 am ET.
Puma Biotechnology, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations